<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-160242" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Vasoplegic Syndrome and Noncatecholamine Therapies</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Heyman</surname>
            <given-names>Heidi M.</given-names>
          </name>
          <aff>University of North Carolina, Department of Anesthesiology</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Serrano</surname>
            <given-names>Ricardo A.</given-names>
          </name>
          <aff>University of North Carolina at Chapel Hill</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Heidi Heyman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ricardo Serrano declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-160242.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Vasoplegic syndrome (VPS) is a rare but life-threatening condition characterized by uncontrolled peripheral vasodilation resulting in profound arterial hypotension in the setting of normal or increased cardiac output.&#x000a0;VPS most frequently occurs&#x000a0;during cardiac surgeries and has been reported in cases of organ transplant, anaphylaxis, and septic shock. Given mortality rates as high as 25%, prompt recognition and implementation of treatments are crucial. While catecholamines are the mainstay of treatment, other therapies such as vasopressin, methylene blue, hydroxocobalamin, angiotensin II, and ascorbic acid have all demonstrated benefits.</p>
        <p>The&#x000a0;pathophysiology&#x000a0;of vasoplegic syndrome&#x000a0;involves a cascade of inflammatory responses and dysregulation of vasoactive substances. Moreover, the variety of risk factors, from prolonged cardiopulmonary bypass to medication history, demands a nuanced understanding that may not be readily available in routine clinical education.</p>
      </sec>
      <sec id="article-160242.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>Cardiac surgery and exposure to an extracorporeal circuit are prevalent contributors to vasoplegia. The risk of VPS increases proportionally with the duration of cardiopulmonary bypass (CPB). Vasoplegia is more likely to happen during cardiac surgery in older people who have longer aortic cross-clamp times or&#x000a0;are prescribed angiotensin-converting enzyme inhibitors (ACEi) or diuretics before surgery.<xref ref-type="bibr" rid="article-160242.r1">[1]</xref>&#x000a0;Liver transplantation is strongly associated with the development of VPS and is a serious perioperative risk factor.<xref ref-type="bibr" rid="article-160242.r2">[2]</xref> Kidney, heart, and lung transplants are also at significantly increased risk for VPS.<xref ref-type="bibr" rid="article-160242.r3">[3]</xref><xref ref-type="bibr" rid="article-160242.r4">[4]</xref> Other risk factors for developing&#x000a0;VPS include blood transfusions, ventricular assist devices, &#x003b2;-blockers, calcium channel blockers, amiodarone, heart failure, and diabetes mellitus.<xref ref-type="bibr" rid="article-160242.r5">[5]</xref><xref ref-type="bibr" rid="article-160242.r6">[6]</xref>&#x000a0;(See Table 1. Clinical risk factors for&#x000a0;VPS for cardiac and non-cardiac surgery).</p>
        <table-wrap id="article-160242.table0" position="float" orientation="portrait">
          <caption>
            <title>Table 1. Clinical risk factors for vasoplegic syndrome for cardiac and non-cardiac surgery.[7]</title>
          </caption>
          <table style="height: 700px; width: 450px;">
            <tbody>
              <tr>
                <td style="width: 224px; border-color: #000000; background-color: #dbe9fa;" rowspan="1" colspan="1">
<p><bold>Cardiac</bold></p>
</td>
                <td style="width: 206px; border-color: #000000; background-color: #dbe9fa;" rowspan="1" colspan="1">
<bold>Non-cardiac</bold>
</td>
              </tr>
              <tr>
                <td style="width: 224px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>Male gender</p>
</td>
                <td style="width: 206px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>Blood transfusions</p>
</td>
              </tr>
              <tr>
                <td style="width: 224px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>BMI &#x0003e; 30 kg/m<sup>2</sup></p>
</td>
                <td style="width: 206px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>Solid organ transplantation</p>
</td>
              </tr>
              <tr>
                <td style="width: 224px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>ESRD</p>
</td>
                <td style="width: 206px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>Trauma</p>
</td>
              </tr>
              <tr>
                <td style="width: 224px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>Presence of LVAD</p>
</td>
                <td style="width: 206px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>Burns</p>
</td>
              </tr>
              <tr>
                <td style="width: 224px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>Prolonged CPB</p>
</td>
                <td style="width: 206px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>Sepsis</p>
</td>
              </tr>
              <tr>
                <td style="width: 224px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>Infective endocarditis</p>
</td>
                <td style="width: 206px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>Pancreatitis</p>
</td>
              </tr>
              <tr>
                <td style="width: 224px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>Use of inodilators</p>
</td>
                <td style="width: 206px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>Heparin</p>
</td>
              </tr>
              <tr>
                <td style="width: 224px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>ACEi or ARBs</p>
</td>
                <td style="width: 206px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>Amiodarone</p>
</td>
              </tr>
              <tr>
                <td style="width: 224px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>Old age</p>
</td>
                <td style="width: 206px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>Metformin</p>
</td>
              </tr>
              <tr>
                <td style="width: 224px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>EF &#x0003c; 35%</p>
</td>
                <td style="width: 206px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>Aprotinin</p>
</td>
              </tr>
              <tr>
                <td style="width: 224px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>DM</p>
</td>
                <td style="width: 206px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>Protamine</p>
</td>
              </tr>
              <tr>
                <td style="width: 224px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>History of MI</p>
</td>
                <td style="width: 206px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>ACEi/ARBs</p>
</td>
              </tr>
              <tr>
                <td style="width: 224px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>High EURO score</p>
</td>
                <td style="width: 206px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>Calcium channel blockers</p>
</td>
              </tr>
              <tr>
                <td style="width: 224px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>High number of blood transfusions</p>
</td>
                <td style="width: 206px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td style="width: 224px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>Combine CABG and valve surgery</p>
</td>
                <td style="width: 206px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
</td>
              </tr>
              <tr>
                <td style="width: 224px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
<p>Diuretic use</p>
</td>
                <td style="width: 206px; border-color: #000000; background-color: #ebf4fa;" rowspan="1" colspan="1">
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>BMI: basic metabolic index, ESRD: end-stage renal disease, LVAD: left ventricular assist device, CPB: cardiopulmonary bypass, EF: ejection fraction, ACEi: angiotensin-converting enzyme inhibitors, ARBs: angiotensin receptor blockers, DM: diabetes mellitus, MI: myocardial infarction, CABG: coronary artery bypass graft.</p>
      </sec>
      <sec id="article-160242.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The incidence of VPS ranges&#x000a0;from 5% to 25% in the cardiac literature.<xref ref-type="bibr" rid="article-160242.r8">[8]</xref> Cases of VPS have also been reported in other surgeries, such as liver transplantation. The lack of consensus on a universal definition for VPS complicates the accurate quantification of VPS cases.<xref ref-type="bibr" rid="article-160242.r9">[9]</xref> Additionally, multiple terms, such as distributive shock, vasoplegic shock, and post-cardiac surgery vasoplegia, describe similar conditions, obscuring&#x000a0;the incidence. VPS is universally fatal if untreated, and mortality rates are as high as 25% with treatment, especially in cases of catecholamine-resistant VPS.<xref ref-type="bibr" rid="article-160242.r10">[10]</xref></p>
      </sec>
      <sec id="article-160242.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Exposure to an extracorporeal circuit during cardiac surgeries is believed to cause cellular damage and stress, leading to a &#x0201c;sterile&#x0201d; inflammatory response commonly referred to as a damage-associated molecular pattern (DAMP). In the same way that pathogen-associated molecular patterns (PAMPs) from infectious microorganisms trigger a strong immune response, DAMPs can cause vasodilation and increased capillary permeability.<xref ref-type="bibr" rid="article-160242.r11">[11]</xref> This vasodilation and capillary permeability can lead to hypotension; the initial systemic response to hypotension is the release of catecholamines. A hyper-catecholaminergic state may result from profound and prolonged hypotension, which can lead to the resistance of catecholamine receptors and the depletion of catecholamine stores. This can cause vascular smooth muscles to constrict in the presence of catecholamines and, therefore, a state of vasodilatory shock.<xref ref-type="bibr" rid="article-160242.r12">[12]</xref></p>
        <p>Such inflammatory mediators also induce nitric oxide synthase, increasing nitric oxide (NO).<xref ref-type="bibr" rid="article-160242.r13">[13]</xref> NO plays a pivotal role in regulating vascular function, and excessive NO production can cause significant vasodilation.<xref ref-type="bibr" rid="article-160242.r14">[14]</xref> Furthermore, hyperpolarization of smooth muscle cells due to NO-induced vasodilation can deplete calcium stores. Controlling vascular tone in normal physiology is largely dependent on calcium concentration. Given calcium&#x02019;s crucial role in smooth muscle contraction, calcium depletion disrupts the intracellular vs. extracellular gradient necessary for maintaining vascular tone. This cascade of events can result in the profound hypotension seen in VPS.<xref ref-type="bibr" rid="article-160242.r15">[15]</xref></p>
        <p>Other substances linked to vasoplegia include adenosine, which activates myocardial mechanoreceptors and affects baroreflex activation. Prostanoids increase during an inflammatory process and cause vasodilation. Endothelin 1 acts as a vasoconstrictor by activating receptors in smooth muscle cells. The renin-angiotensin-aldosterone system that regulates blood pressure and fluid balance can become dysregulated in vasoplegia. Hydrogen sulfide, produced during homocysteine metabolism, can activate ATP-sensitive potassium channels, leading to hyperpolarization and&#x000a0;reduced&#x000a0;vascular tone.<xref ref-type="bibr" rid="article-160242.r16">[16]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-160242.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>When evaluating a patient's risk for VPS, it is important to consider medical history for possible risk factors. These may include prolonged cardiopulmonary bypass or aortic cross-clamp time, advanced age, pre-operative use of angiotensin-converting enzyme inhibitors (ACEi), and renal failure. (See Table 1.<bold>&#x000a0;</bold>Clinical risk factors for vasoplegic syndrome for cardiac and non-cardiac surgery.)</p>
        <p>The physical signs of circulatory failure encompass the clinical manifestations of hypotension, which&#x000a0;are not universally present. Patients may have warm extremities&#x000a0;after low blood pressure due to vasodilation. The heart rate is typically within normal or elevated ranges as the body tries to compensate for low systemic vascular resistance. Lastly, signs of inadequate tissue perfusion can manifest as mottling or delayed capillary refill.&#x000a0;Decreased urine output, measuring less than 0.5 ml/kg/min, and altered mental function may exist, including obtundation and confusion.</p>
      </sec>
      <sec id="article-160242.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>VPS&#x000a0;is a form of vasodilatory shock characterized by abnormally low systemic vascular resistance and hypotension with normal or increased cardiac output (see Table 2. Characteristics of vasoplegic syndrome).<xref ref-type="bibr" rid="article-160242.r11">[11]</xref>&#x000a0; Several organizations have proposed specific parameters for mean arterial pressure and cardiac output to define VPS, but these definitions have yet to be universally accepted.<xref ref-type="bibr" rid="article-160242.r17">[17]</xref> Historical records trace the recognition of vasoplegia back to the early 1950s.<xref ref-type="bibr" rid="article-160242.r18">[18]</xref> However, recent decades have brought attention to&#x000a0;the role in causing refractory hypotension during organ transplantation, cardiac surgery, anaphylaxis, and septic shock.<xref ref-type="bibr" rid="article-160242.r19">[19]</xref>&#x000a0;</p>
        <table-wrap id="article-160242.table1" position="float" orientation="portrait">
          <caption>
            <title>Table 2. Characteristics of vasoplegic syndrome</title>
          </caption>
          <table style="height: 193px; width: 800px;">
            <tbody>
              <tr style="height: 85px; border-color: #000000;">
                <td style="width: 69.7344px; height: 85px; border-color: #000000; vertical-align: middle; text-align: center;" rowspan="1" colspan="1">
<p><bold>CI</bold></p>
</td>
                <td style="width: 73.2656px; height: 85px; border-color: #000000; vertical-align: middle; text-align: center;" rowspan="1" colspan="1">
<p><bold>&#x000a0;</bold></p>
<p><bold>MAP</bold></p>
<p><bold>&#x000a0;</bold></p>
</td>
                <td style="width: 78px; height: 85px; border-color: #000000; vertical-align: middle; text-align: center;" rowspan="1" colspan="1">
<p><bold>SVR</bold></p>
</td>
                <td style="width: 76px; height: 85px; border-color: #000000; vertical-align: middle; text-align: center;" rowspan="1" colspan="1">
<p><bold>&#x000a0;</bold></p>
<p><bold>HR&#x000a0;</bold></p>
<p><bold>&#x000a0;</bold></p>
</td>
                <td style="width: 57px; height: 85px; border-color: #000000; vertical-align: middle; text-align: center;" rowspan="1" colspan="1">
<p><bold>RAP</bold></p>
</td>
                <td style="width: 56px; height: 85px; border-color: #000000; vertical-align: middle; text-align: center;" rowspan="1" colspan="1">
<p><bold>LAP</bold></p>
</td>
                <td style="width: 65px; height: 85px; border-color: #000000; vertical-align: middle; text-align: center;" rowspan="1" colspan="1">
<p><bold>PCWP</bold></p>
</td>
                <td style="width: 64px; height: 85px; border-color: #000000; vertical-align: middle; text-align: center;" rowspan="1" colspan="1">
<p><bold>MPAP</bold></p>
</td>
                <td style="width: 100px; height: 85px; border-color: #000000; vertical-align: middle; text-align: center;" rowspan="1" colspan="1">
<p><bold>Vasopressor Dose</bold></p>
</td>
                <td style="width: 89px; height: 85px; border-color: #000000; vertical-align: middle; text-align: center;" rowspan="1" colspan="1">
<p><bold>Volume Expansion Response</bold></p>
</td>
              </tr>
              <tr style="height: 70.2031px;">
                <td style="width: 69.7344px; height: 70.2031px; border-color: #000000; vertical-align: middle; text-align: center;" rowspan="1" colspan="1">
<p>&#x02265;&#x000a0;2.2&#x000a0; &#x000a0; L/min/m<sup>2</sup></p>
</td>
                <td style="width: 73.2656px; height: 70.2031px; border-color: #000000; vertical-align: middle; text-align: center;" rowspan="1" colspan="1">
<p>&#x0003c; 60 mmHg</p>
</td>
                <td style="width: 78px; height: 70.2031px; border-color: #000000; vertical-align: middle; text-align: center;" rowspan="1" colspan="1">
<p>&#x0003c;800 dynes*&#x000a0; &#x000a0;sec/cm<sup>5</sup></p>
</td>
                <td style="width: 76px; height: 70.2031px; border-color: #000000; vertical-align: middle; text-align: center;" rowspan="1" colspan="1">
<bold>&#x02191;</bold>
</td>
                <td style="width: 57px; height: 70.2031px; border-color: #000000; vertical-align: middle; text-align: center;" rowspan="1" colspan="1">
<bold>&#x02193;&#x000a0;</bold>
</td>
                <td style="width: 56px; height: 70.2031px; border-color: #000000; vertical-align: middle; text-align: center;" rowspan="1" colspan="1">
<bold>&#x000a0;&#x02193;</bold>
</td>
                <td style="width: 65px; height: 70.2031px; border-color: #000000; vertical-align: middle; text-align: center;" rowspan="1" colspan="1">
<bold>&#x000a0;&#x02193;</bold>
</td>
                <td style="width: 64px; height: 70.2031px; border-color: #000000; vertical-align: middle; text-align: center;" rowspan="1" colspan="1">
<bold>&#x000a0;&#x02193;</bold>
</td>
                <td style="width: 100px; height: 70.2031px; border-color: #000000; vertical-align: middle; text-align: center;" rowspan="1" colspan="1">
<p>0.5 &#x000b5;g/kg/min of norepinephrine equivalents</p>
</td>
                <td style="width: 89px; height: 70.2031px; border-color: #000000; vertical-align: middle; text-align: center;" rowspan="1" colspan="1">
<p>Irresponsive</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>CI: cardiac index, MAP: mean arterial pressure, SVR: systemic vascular resistance, HR: heart rate, RAP: right atrial pressure, LAP: left atrial pressure, PCWP: pulmonary capillary wedge pressure, MPAP: mean pulmonary artery pressure</p>
      </sec>
      <sec id="article-160242.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Vasoplegic syndrome is a medical condition characterized by persistent hypotension and vasodilation. Traditional catecholamine therapies may&#x000a0;be insufficient or pose adverse effects in this syndrome. Alternative treatment options must be explored and considered to address the therapeutic challenges of vasoplegia. Non-catecholamine treatments, such as vasopressin, methylene blue, hydroxocobalamin, angiotensin II, and ascorbic acid (vitamin C), offer distinct mechanisms of action (see Table 3. Summary of non-catecholamine therapies for the treatment of vasoplegic syndrome, dosing, mechanism of action, adverse effects, and advantages).</p>
        <p>Vasoplegic syndrome&#x000a0;is managed through non-catecholamine approaches that&#x000a0;show promising potential. These approaches work by restoring vascular tone and inhibiting critical enzymes in vasodilation. This compilation explores the mechanisms underlying each therapy and addresses essential considerations such as dosing, adverse effects, and the associated advantages. As the medical community continues to seek optimal strategies for treating vasoplegia, this resource provides insights for understanding and implementing non-catecholamine therapies in clinical practice.</p>
        <p>
<bold>Vasopressin</bold>
</p>
        <p>When high doses of catecholamines&#x000a0;are&#x000a0;ineffective for maintaining blood pressure or result in adverse effects, vasopressin may be&#x000a0;utilized&#x000a0;as an additional treatment option. Vasopressin (at doses up to 0.03 &#x000b5;mol/min) is used as a second-line or extra treatment for catecholamine-resistant vasodilatory shock.<xref ref-type="bibr" rid="article-160242.r19">[19]</xref> By acting on the vasopressin receptor 1, it reinstates vascular tone. Vasopressin directly deactivates the K-ATP channel, inhibiting the increase in cGMP caused by NO, reducing NO synthesis, and minimizing the effects of membrane hyperpolarization, myosin dephosphorylation, and NO accumulation.<xref ref-type="bibr" rid="article-160242.r20">[20]</xref> These actions make vasopressin a viable alternative when high doses of catecholamines are ineffective or unsafe.</p>
        <p>
<bold>Methylene Blue</bold>
</p>
        <p>Methylene blue is a potential treatment option for VPS. However, the evidence supporting&#x000a0;the effectiveness&#x000a0;is from retrospective cohort studies and case reports. Further research is needed to determine the impact of methylene blue on clinical outcomes such as morbidity and mortality. Nevertheless, a study by Levin et al suggests that methylene blue can reduce mortality and morbidity following cardiac surgery in cases of vasoplegia. The evidence indicates that methylene blue therapy can effectively improve hemodynamic parameters and reduce the need for vasopressors, preventing adverse effects such as mesenteric ischemia or tissue necrosis.<xref ref-type="bibr" rid="article-160242.r1">[1]</xref>&#x000a0;</p>
        <p>The mechanism of action of methylene blue involves inhibiting&#x000a0;2 enzymes, namely NO synthase and guanylyl cyclase. This inhibition leads to a reduction in the vasodilatory effects of cytokines that are released in response to shock. Additionally, the binding affinity for the M3 receptor exerts inhibitory effects on cholinesterase activity.&#x000a0;Methylene blue should be avoided in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, and caution should be exercised when administering serotonin-metabolizing drugs. Methylene blue is considered a safe treatment option for different shock states. In the case of distributive shock, an infusion of 1 to 2 mg/kg may be administered over 10 to 20 minutes to an hour. In cases where a continuous infusion is required, a preload followed by a continuous infusion of 1 mg/kg per hour over 48 to 72 hours&#x000a0;has significant benefits without adversely affecting splanchnic circulation.<xref ref-type="bibr" rid="article-160242.r21">[21]</xref>&#x000a0;</p>
        <p>
<bold>Hydroxocobalamin</bold>
</p>
        <p>Hydroxocobalamin is a derivative of vitamin B12 that has potential as a rescue strategy for treating vasoplegia after cardiac surgery&#x02014;the vitamin&#x000a0;works by inhibiting NO synthase and guanylate cyclase. A systematic review by Brokmeier et al&#x000a0;<xref ref-type="bibr" rid="article-160242.r22">[22]</xref> analyzed 24 published manuscripts and conducted a meta-analysis of 3 cohort studies to evaluate the use of hydroxocobalamin in vasodilatory hypotension. The results showed that hydroxocobalamin was associated with a more significant increase in MAP than methylene blue, but neither agent significantly impacted the change in MAP from baseline or mortality. Hydroxocobalamin therapy in VPS is limited and can cause chromaturia and slight interference with common laboratory measurements.<xref ref-type="bibr" rid="article-160242.r23">[23]</xref> A daily 5 g bolus dose should be administered for 10 to 15 minutes and repeated for up to 48 hours after cardiac surgery, according to Muhammad et al.<xref ref-type="bibr" rid="article-160242.r24">[24]</xref>&#x000a0;The daily dose is often a final recourse when all alternative therapeutic alternatives&#x000a0;are ineffective in producing significant improvements.&#x000a0;</p>
        <p>
<bold>Angiotensin II</bold>
</p>
        <p>Angiotensin II is considered a treatment option for vasoplegia when high-dose vasopressors fail.&#x000a0;This can be implemented in catecholamine-induced mesenteric ischemia due to angiotensin II&#x02019;s ability to mobilize venous blood from mesenteric arteries and stimulate lactate clearance.<xref ref-type="bibr" rid="article-160242.r25">[25]</xref>&#x000a0;The peptide is responsible for the vasoconstrictive effects of the renin-angiotensin-aldosterone system (RAAS) via impact on the AT-1 receptor in vascular smooth muscle.&#x000a0;</p>
        <p>Angiotensin II can also treat hypotension by increasing the release of aldosterone and vasopressin from the posterior pituitary, increasing the body&#x02019;s sympathetic response.<xref ref-type="bibr" rid="article-160242.r16">[16]</xref> Notable adverse effects include arterial and venous thrombotic events, thrombocytopenia, tachycardia, decreased cardiac output, lactic acidosis, delirium, and a higher incidence of fungal infections. The recommended starting dose for continuous infusion is 20 ng/kg, and&#x000a0;is titrated every 5 minutes, up to 80 ng/kg during the first 3 hours.<xref ref-type="bibr" rid="article-160242.r26">[26]</xref></p>
        <p>
<bold>Ascorbic Acid (Vitamin C)</bold>
</p>
        <p>Ascorbic acid has demonstrated benefits as a treatment.&#x000a0;The vitamin can reduce the dose requirements of other vasopressors and lessen the potential for adverse effects. Ascorbic acid is an essential cofactor in catecholamine synthesis, and exogenous administration increases&#x000a0;vasopressor synthesis in the adrenal medulla.<xref ref-type="bibr" rid="article-160242.r24">[24]</xref> After CPB, vitamin C levels are notably diminished, causing a reduction in the synthesis of vasopressors.<xref ref-type="bibr" rid="article-160242.r27">[27]</xref> Consequently, administering ascorbic acid treatment when vitamin C levels are deficient could improve the production of endogenous vasopressors. A few studies have examined combining ascorbic acid with hydrocortisone and thiamine, termed &#x0201c;HAT&#x0201d; therapy, which may be beneficial, but additional research is needed.<xref ref-type="bibr" rid="article-160242.r28">[28]</xref></p>
        <p>Typical administration of ascorbic acid as a treatment for VPS is one 6 g IV bolus dose per day. The recommended dose of hydrocortisone is 50 mg IV bolus every 6 hours or 100 mg every 8 hours, and the dose for thiamine is 400 mg IV daily.<xref ref-type="bibr" rid="article-160242.r29">[29]</xref></p>
        <table-wrap id="article-160242.table2" position="float" orientation="portrait">
          <caption>
            <title>Table 3. Summary of non-catecholamine therapies for the treatment of vasoplegic syndrome, dosing, mechanism of action, adverse effects, and advantages</title>
          </caption>
          <table style="border-color: black; width: 900px;" cellpadding="5">
            <tbody>
              <tr>
                <td style="width: 122.328px;" rowspan="1" colspan="1">
<p><bold>&#x000a0; &#x000a0; &#x000a0;Drug Name</bold></p>
</td>
                <td style="width: 177.797px; padding-left: 30px;" rowspan="1" colspan="1">
<p><bold>Mechanism of Action</bold></p>
</td>
                <td style="width: 199.453px; padding-left: 30px;" rowspan="1" colspan="1">
<p><bold>&#x000a0; Dosing</bold></p>
</td>
                <td style="width: 300.656px; padding-left: 30px;" rowspan="1" colspan="1">
<p><bold>&#x000a0; Adverse Effects</bold></p>
</td>
                <td style="width: 249.766px; padding-left: 30px;" rowspan="1" colspan="1">
<p><bold>Advantages and outcomes</bold></p>
</td>
              </tr>
              <tr>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>Vasopressin</p>
</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>V1 receptor agonism; repletion of vasopressin in ADH-depleted states</p>
</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>Infusion doses up to 0.03 &#x000b5;mol/min</p>
</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>Risk of bradycardia in patients receiving catecholamine therapy, coronary vasoconstriction, decreased cardiac output (avoid in cardiogenic shock), thrombocytopenia, mesenteric ischemia, distal limb ischemia, and increased bilirubin concentration</p>
</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>As a first-line agent, it may help reduce the dose of catecholamine needed to achieve the desired mean arterial pressure (MAP) goal. It may also help reduce the severity of renal failure. However, there is no significant difference in mortality benefits compared to norepinephrine.</p>
</td>
              </tr>
              <tr>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>Methylene blue</p>
</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>Inhibition of guanylyl cyclase and inducible endothelial NO synthase</p>
</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>1 to 2 mg/kg infusion for 10 to 60 minutes or a preload followed by a continuous infusion of 1 mg/kg per hour over 48 to 72 hours</p>
</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>Can trigger serotonin syndrome in patients taking monoamine oxidase inhibitors and selective serotonin inhibitors (SSRI). Contraindicated in G6PD deficiency due to risk of hemolytic anemia; can interfere with pulse oximetry</p>
</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>Used as preventive and rescue therapy. In single boluses, it may rapidly improve MAP in severe vasoplegia. It is retrospectively associated with mortality benefits when given early in vasoplegic shock.</p>
</td>
              </tr>
              <tr>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>Hydroxocobalamin (Vitamin B12)</p>
</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>Inhibition of NO directly and inducible endothelial NO synthase</p>
<p>Inhibition of hydrogen sulfide</p>
</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>5 g bolus for 10 to 15 minutes/day; can be repeated for up to 48 hours</p>
</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>Chromaturia (may last several weeks and has the potential to interfere with hemodialysis machines, causing false blood leak alarms), nausea, erythema, nephrolithiasis, lymphocytopenia, and infusion site reactions</p>
</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>It can decrease the need for other vasopressors, lower mortality rates, and is often used as a rescue agent. Additionally, it raises MAP and avoids certain risks associated with methylene blue.</p>
</td>
              </tr>
              <tr>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>Angiotensin II</p>
</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>Agonist for angiotensin I and leads to vasoconstriction.</p>
<p>Stimulates aldosterone release.</p>
<p>Increase in ADH synthesis.</p>
</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>10 to 40&#x02009;ng/kg/min</p>
</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>Arterial and venous thrombotic events, thrombocytopenia, tachycardia, decreased cardiac output (avoid in cardiogenic shock), lactic acidosis, delirium, and higher incidence of fungal infections. It may interfere with endogenous vasopressin synthesis.&#x000a0;</p>
</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>It may significantly improve mean arterial pressure and reduce the need for catecholamines. A recent randomized controlled trial showed improved hemodynamics compared to a placebo.</p>
</td>
              </tr>
              <tr>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>Ascorbic acid (Vitamin C)</p>
</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>Cofactor for catecholamine synthesis</p>
</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>6 g IV daily</p>
</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>Limited safety and efficacy data</p>
</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>The effectiveness of HAT (hydrocortisone, ascorbic acid, thiamine) therapy in reducing mortality rates for patients diagnosed with sepsis is not well-established. Most clinical studies have not reported any serious adverse effects of HAT therapy, indicating that this treatment has a good safety profile.</p>
</td>
              </tr>
              <tr>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>Thiamine</p>
<p>(Vitamin B1)</p>
</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">Cofactor for lactate dehydrogenase, which aids in lactate clearance</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">400 mg IV daily&#x000a0;</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">Limited safety and efficacy data&#x000a0;</td>
                <td style="width: 278.766px;" rowspan="1" colspan="1">&#x000a0;</td>
              </tr>
              <tr>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>Corticosteroids / Hydrocortisone</p>
</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>Aids in vitamin C metabolism, inhibits pro-inflammatory cytokines, and repletion of glucocorticoid and mineralocorticoid activity in the cortisol-depleted state</p>
</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>50 mg bolus every 6 hours or 100 mg every 8 hours</p>
</td>
                <td style="width: 122.328px; text-align: center; vertical-align: middle;" rowspan="1" colspan="1">
<p>In cardiac surgery, corticosteroids can increase the perioperative risk of complications such as delayed wound healing, poor glucose control, and gastrointestinal bleeding</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-160242.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>VPS&#x000a0;has a distinctive hemodynamic profile compared to other hemodynamic states, such as hypovolemic shock. The latter is triggered by a reduction in intravascular volume due to fluid loss or hemorrhage, leading to a decline in cardiac output. In response to this, vascular tone increases to maintain blood pressure. In contrast, cardiogenic shock occurs when there is inadequate cardiac function following a myocardial infarction or severe heart failure. This results in decreased cardiac output and increased systemic vascular resistance due to compensatory vasoconstriction. Therefore, the&#x000a0;2 conditions entail distinct pathophysiological mechanisms and warrant different management strategies.</p>
      </sec>
      <sec id="article-160242.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of patients who develop&#x000a0;VPS depends on the underlying etiology and the presence of risk factors. The duration of vasoplegia can extend to as much as 72 hours, and&#x000a0;the occurrence is associated with increased mortality rates of up to 25%.<xref ref-type="bibr" rid="article-160242.r3">[3]</xref>&#x000a0;Orthotopic heart transplantation is linked with high early mortality rates, as high as 25%.<xref ref-type="bibr" rid="article-160242.r30">[30]</xref></p>
        <p>Vasopressor dependence&#x000a0;is identified as a significant morbid event in the postoperative phase of patients after cardiac operations. This underscores the need for risk stratification as an essential issue for prophylactic and early therapeutic concepts. Vasopressin and methylene blue are examples of non-catecholamine therapies that reduce dependence on vasopressors and improve outcomes. The treatment of vasopressor dependence is associated with improved outcomes, strengthening the need for further evaluation in large cohorts of patients.<xref ref-type="bibr" rid="article-160242.r31">[31]</xref></p>
      </sec>
      <sec id="article-160242.s10" sec-type="Complications">
        <title>Complications</title>
        <p>Patients suffering from this condition require extended periods of ventilation. Furthermore,&#x000a0;after&#x000a0;comparable blood losses, they necessitate significantly more transfusions of packed red blood cells. They also require a greater need for fresh frozen plasma, are at risk of acute renal failure, and experience delayed discharge from the intensive care unit.</p>
      </sec>
      <sec id="article-160242.s11" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>VPS&#x000a0;is when the blood vessels in the body&#x000a0;are too relaxed, causing low blood pressure when the heart is functioning normally. This condition typically occurs after certain types of surgeries, especially heart surgeries, or in other situations such as sepsis, trauma, lung, heart, and liver transplants. Several risk factors can increase the likelihood of developing&#x000a0;VPS, such as heart failure, older age, diabetes, male gender, obesity, or taking certain medications like amiodarone, angiotensin-converting enzyme inhibitors, and calcium-channel blockers. Patients with&#x000a0;VPS may require fluids and vasopressor medications to increase blood pressure and improve blood flow. Vasopressors work by constricting blood vessels and increasing resistance to blood flow.</p>
        <p>Although&#x000a0;VPS is usually a temporary condition, organ failure or death may ensue if not treated promptly and effectively.</p>
      </sec>
      <sec id="article-160242.s12" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>VPS&#x000a0;is characterized by persistently low systemic vascular resistance, leading to profound hypotension and vasodilation despite a normal or high cardiac index. This condition is most prevalent in cardiac surgeries following cardiopulmonary bypass but can also be observed due to organ transplantation, anaphylaxis, or sepsis. Early identification and treatment are crucial since mortality rates reach up to 25%. Norepinephrine is the first-line treatment for VPS, while vasopressin is typically used as a second-line agent in catecholamine-resistant VPS in infusion doses of up to 0.03 &#x000b5;mol/min.</p>
        <p>Other rescue therapies include methylene blue, hydroxocobalamin, angiotensin II, and ascorbic acid, with or without thiamine and hydrocortisone. Methylene blue is administered in 1 to 2 mg/kg infusion for 10 to 60 minutes, followed by a continuous infusion of 1 mg/kg per hour over 48 to 72 hours. Hydroxocobalamin involves a 5 g bolus for 10 to 15 minutes daily, repeated for up to 48 hours. On the other hand, angiotensin II requires a 20 ng/kg starting infusion and can be titrated to effect every 5 minutes for up to 80 ng/kg during the first 3 hours. Finally, ascorbic acid is administered through 6 g IV daily, with or without thiamine (400 mg IV daily) and hydrocortisone (50 mg bolus every 6 hours or 100 mg every 8 hours).</p>
      </sec>
      <sec id="article-160242.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>VPS&#x000a0;is a deadly condition characterized by hypotension due to low systemic vascular resistance despite a normal or high cardiac index.&#x000a0;The condition is most frequently&#x000a0;reported in cardiac surgeries following cardiopulmonary bypass but can also occur due to organ transplantation, anaphylaxis, and septic shock. Multiple risk factors&#x000a0;are identified, including prolonged CPB or aortic cross-clamp time, advanced age, pre-operative use of angiotensin-converting enzyme inhibitors (ACEI), and renal failure. Early identification and treatment are crucial. Norepinephrine is the first-line treatment, followed by adding vasopressin and other non-catecholamine vasopressors.</p>
        <p>Caring for patients who develop&#x000a0;VPS necessitates a collaborative approach among healthcare professionals to improve overall outcomes. Anesthesiologists, critical care clinicians, advanced practitioners, nurses, pharmacists, and other health professionals involved in the care of these patients should possess the essential clinical skills and knowledge to diagnose and manage VPS. Exploring non-catecholamine therapies necessitates a collective effort in VPS. Collaborative decision-making ensures the chosen interventions are evidence-based and meet the patient's needs. Ultimately, this integrated approach fosters a patient-centric paradigm, optimizing care quality and achieving superior outcomes in the challenging landscape of&#x000a0;VPS management.</p>
      </sec>
      <sec id="article-160242.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=160242&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=160242">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/heart-health/vasoplegic-syndrome-and-noncatecholamine-therapies/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=160242">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/160242/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=160242">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-160242.s15">
        <title>References</title>
        <ref id="article-160242.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levin</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Castillo</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Reich</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>GW</given-names>
              </name>
            </person-group>
            <article-title>Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome.</article-title>
            <source>Circulation</source>
            <year>2009</year>
            <month>Oct</month>
            <day>27</day>
            <volume>120</volume>
            <issue>17</issue>
            <fpage>1664</fpage>
            <page-range>1664-71</page-range>
            <pub-id pub-id-type="pmid">19822810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fischer</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Bengtsson</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Scarola</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Methylene blue for vasopressor-resistant vasoplegia syndrome during liver transplantation.</article-title>
            <source>J Cardiothorac Vasc Anesth</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>463</fpage>
            <page-range>463-6</page-range>
            <pub-id pub-id-type="pmid">18835528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Byrne</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Leacche</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mihaljevic</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rawn</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Shernan</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Mudge</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
            </person-group>
            <article-title>Risk factors and outcomes for 'vasoplegia syndrome' following cardiac transplantation.</article-title>
            <source>Eur J Cardiothorac Surg</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>327</fpage>
            <page-range>327-32</page-range>
            <pub-id pub-id-type="pmid">15019656</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carley</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schaff</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Poppers</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Methylene Blue for Vasoplegia When on Cardiopulmonary Bypass During Double-Lung Transplantation.</article-title>
            <source>A A Case Rep</source>
            <year>2015</year>
            <month>Oct</month>
            <day>15</day>
            <volume>5</volume>
            <issue>8</issue>
            <fpage>127</fpage>
            <page-range>127-30</page-range>
            <pub-id pub-id-type="pmid">26466303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hershman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hadash</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Attias</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ben-Ari</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Methylene blue treatment for resistant shock following renal transplantation.</article-title>
            <source>Paediatr Anaesth</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>25</volume>
            <issue>11</issue>
            <fpage>1168</fpage>
            <page-range>1168-9</page-range>
            <pub-id pub-id-type="pmid">26428738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patarroyo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simbaqueba</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Starling</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Smedira</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>DO</given-names>
              </name>
            </person-group>
            <article-title>Pre-operative risk factors and clinical outcomes associated with vasoplegia in recipients of orthotopic heart transplantation in the contemporary era.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>282</fpage>
            <page-range>282-7</page-range>
            <pub-id pub-id-type="pmid">22112993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bastopcu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sarg&#x00131;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kuplay</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Erdo&#x0011f;an</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Yap&#x00131;c&#x00131;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Aka</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for vasoplegia after coronary artery bypass and valve surgery.</article-title>
            <source>J Card Surg</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>36</volume>
            <issue>8</issue>
            <fpage>2729</fpage>
            <page-range>2729-2734</page-range>
            <pub-id pub-id-type="pmid">34018257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fischer</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Vasoplegia during cardiac surgery: current concepts and management.</article-title>
            <source>Semin Thorac Cardiovasc Surg</source>
            <year>2010</year>
            <season>Summer</season>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>140</fpage>
            <page-range>140-4</page-range>
            <pub-id pub-id-type="pmid">21092891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sakpal</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Reedstrom</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ness</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Klinkhammer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Saucedo-Crespo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Auvenshine</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Santella</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Steers</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>High-dose hydroxocobalamin in end-stage liver disease and liver transplantation.</article-title>
            <source>Drugs Ther Perspect</source>
            <year>2019</year>
            <volume>35</volume>
            <issue>9</issue>
            <fpage>442</fpage>
            <page-range>442-446</page-range>
            <pub-id pub-id-type="pmid">32288505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gomes</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Carvalho</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Palma</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Teles</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Branco</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Silas</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Buffolo</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Vasoplegic syndrome after open heart surgery.</article-title>
            <source>J Cardiovasc Surg (Torino)</source>
            <year>1998</year>
            <month>Oct</month>
            <volume>39</volume>
            <issue>5</issue>
            <fpage>619</fpage>
            <page-range>619-23</page-range>
            <pub-id pub-id-type="pmid">9833722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lambden</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Creagh-Brown</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Summers</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Forni</surname>
                <given-names>LG</given-names>
              </name>
            </person-group>
            <article-title>Definitions and pathophysiology of vasoplegic shock.</article-title>
            <source>Crit Care</source>
            <year>2018</year>
            <month>Jul</month>
            <day>06</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>174</fpage>
            <pub-id pub-id-type="pmid">29980217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lahiry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thakur</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chakraborty</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Advances in Vasodilatory Shock: A Concise Review.</article-title>
            <source>Indian J Crit Care Med</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>10</issue>
            <fpage>475</fpage>
            <page-range>475-480</page-range>
            <pub-id pub-id-type="pmid">31749557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lenz</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Hepatorenal syndrome--is it central hypovolemia, a cardiac disease, or part of gradually developing multiorgan dysfunction?</article-title>
            <source>Hepatology</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>263</fpage>
            <page-range>263-5</page-range>
            <pub-id pub-id-type="pmid">16025501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uyanga</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Jiao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Onagbesan</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Effects of arginine replacement with L-citrulline on the arginine/nitric oxide metabolism in chickens: An animal model without urea cycle.</article-title>
            <source>J Anim Sci Biotechnol</source>
            <year>2023</year>
            <month>Feb</month>
            <day>01</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <pub-id pub-id-type="pmid">36721201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ltaief</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ben-Hamouda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rancati</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gunga</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Marcucci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kirsch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liaudet</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Vasoplegic Syndrome after Cardiopulmonary Bypass in Cardiovascular Surgery: Pathophysiology and Management in Critical Care.</article-title>
            <source>J Clin Med</source>
            <year>2022</year>
            <month>Oct</month>
            <day>29</day>
            <volume>11</volume>
            <issue>21</issue>
            <pub-id pub-id-type="pmid">36362635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ratnani</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ochani</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Shaikh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jatoi</surname>
                <given-names>HN</given-names>
              </name>
            </person-group>
            <article-title>Vasoplegia: A Review.</article-title>
            <source>Methodist Debakey Cardiovasc J</source>
            <year>2023</year>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>38</fpage>
            <page-range>38-47</page-range>
            <pub-id pub-id-type="pmid">37547893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ortoleva</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Cobey</surname>
                <given-names>FC</given-names>
              </name>
            </person-group>
            <article-title>A Systematic Approach to the Treatment of Vasoplegia Based on Recent Advances in Pharmacotherapy.</article-title>
            <source>J Cardiothorac Vasc Anesth</source>
            <year>2019</year>
            <month>May</month>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>1310</fpage>
            <page-range>1310-1314</page-range>
            <pub-id pub-id-type="pmid">30598380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Evora</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Alves Junior</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Menardi</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Bassetto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Scorzoni Filho</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vicente</surname>
                <given-names>WV</given-names>
              </name>
            </person-group>
            <article-title>Twenty years of vasoplegic syndrome treatment in heart surgery. Methylene blue revised.</article-title>
            <source>Rev Bras Cir Cardiovasc</source>
            <year>2015</year>
            <season>Jan-Mar</season>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>84</fpage>
            <page-range>84-92</page-range>
            <pub-id pub-id-type="pmid">25859872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fritz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tahon</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jacquot</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Auchet</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kimmoun</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Vasoplegia treatments: the past, the present, and the future.</article-title>
            <source>Crit Care</source>
            <year>2018</year>
            <month>Feb</month>
            <day>27</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>52</fpage>
            <pub-id pub-id-type="pmid">29486781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holmes</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Landry</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Granton</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Science review: Vasopressin and the cardiovascular system part 1--receptor physiology.</article-title>
            <source>Crit Care</source>
            <year>2003</year>
            <month>Dec</month>
            <volume>7</volume>
            <issue>6</issue>
            <fpage>427</fpage>
            <page-range>427-34</page-range>
            <pub-id pub-id-type="pmid">14624682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Puntillo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Giglio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pasqualucci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brienza</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Paladini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Varrassi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Vasopressor-Sparing Action of Methylene Blue in Severe Sepsis and Shock: A Narrative Review.</article-title>
            <source>Adv Ther</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>37</volume>
            <issue>9</issue>
            <fpage>3692</fpage>
            <page-range>3692-3706</page-range>
            <pub-id pub-id-type="pmid">32705530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brokmeier</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Seelhammer</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Nei</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Gerberi</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Mara</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Wittwer</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Wieruszewski</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Hydroxocobalamin for Vasodilatory Hypotension in Shock: A Systematic Review With Meta-Analysis for Comparison to Methylene Blue.</article-title>
            <source>J Cardiothorac Vasc Anesth</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>37</volume>
            <issue>9</issue>
            <fpage>1757</fpage>
            <page-range>1757-1772</page-range>
            <pub-id pub-id-type="pmid">37147207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shapeton</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Mahmood</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ortoleva</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Hydroxocobalamin for the Treatment of Vasoplegia: A Review of Current Literature and Considerations for Use.</article-title>
            <source>J Cardiothorac Vasc Anesth</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>894</fpage>
            <page-range>894-901</page-range>
            <pub-id pub-id-type="pmid">30217583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muhammad</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dharmadjati</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Mulia</surname>
                <given-names>EPB</given-names>
              </name>
              <name>
                <surname>Rachmi</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Vasoplegia: Mechanism and Management Following Cardiopulmonary Bypass.</article-title>
            <source>Eurasian J Med</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>92</fpage>
            <page-range>92-99</page-range>
            <pub-id pub-id-type="pmid">35307639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papazisi</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Palmen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Danser</surname>
                <given-names>AHJ</given-names>
              </name>
            </person-group>
            <article-title>The Use of Angiotensin II for the Treatment of Post-cardiopulmonary Bypass Vasoplegia.</article-title>
            <source>Cardiovasc Drugs Ther</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>739</fpage>
            <page-range>739-748</page-range>
            <pub-id pub-id-type="pmid">33085026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bauer</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Sacha</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>Safe Use of Vasopressin and Angiotensin II for Patients with Circulatory Shock.</article-title>
            <source>Pharmacotherapy</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>38</volume>
            <issue>8</issue>
            <fpage>851</fpage>
            <page-range>851-861</page-range>
            <pub-id pub-id-type="pmid">29878459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodemeister</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Duquesne</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Adolph</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nohr</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Biesalski</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Unertl</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Massive and long-lasting decrease in vitamin C plasma levels as a consequence of extracorporeal circulation.</article-title>
            <source>Nutrition</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>673</fpage>
            <page-range>673-8</page-range>
            <pub-id pub-id-type="pmid">24631388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marik</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Khangoora</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rivera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hooper</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Catravas</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study.</article-title>
            <source>Chest</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>151</volume>
            <issue>6</issue>
            <fpage>1229</fpage>
            <page-range>1229-1238</page-range>
            <pub-id pub-id-type="pmid">27940189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balakrishnan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pandya</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Keshwani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yadav</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Hydrocortisone, Vitamin C and thiamine for the treatment of sepsis and septic shock following cardiac surgery.</article-title>
            <source>Indian J Anaesth</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>62</volume>
            <issue>12</issue>
            <fpage>934</fpage>
            <page-range>934-939</page-range>
            <pub-id pub-id-type="pmid">30636793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kilger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Beiras-Fernandez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nassau</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Reuter</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Goetz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lamm</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Reindl</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Briegel</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Association between vasopressor dependence and early outcome in patients after cardiac surgery.</article-title>
            <source>Anaesthesia</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>61</volume>
            <issue>10</issue>
            <fpage>938</fpage>
            <page-range>938-42</page-range>
            <pub-id pub-id-type="pmid">16978306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-160242.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kofler</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Simbeck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tomasi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hinske</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Klotz</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Uhle</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Born</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pichlmaier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hagl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Weigand</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Zwi&#x000df;ler</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>von Dossow</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Early Use of Methylene Blue in Vasoplegic Syndrome: A 10-Year Propensity Score-Matched Cohort Study.</article-title>
            <source>J Clin Med</source>
            <year>2022</year>
            <month>Feb</month>
            <day>20</day>
            <volume>11</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">35207394</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
